Industry News
Managing the Side Effects of CAR-T Cell Therapy: Key Insights from Recent Research
This news article highlights recent research on managing the toxicities of CAR-T cell therapy for B-cell lymphomas. The study emphasizes strategies to handle common side effects like cytokine release syndrome (CRS) and neurotoxicity (ICANS), ensuring safer use of this groundbreaking treatment.
Long-Term Efficacy of CD19 CAR T-Cell Therapy in Treating Relapsed/Refractory Acute Lymphoblastic Leukemia
A groundbreaking study demonstrates the long-term success of CD19 CAR T-cell therapy in treating patients with relapsed/refractory acute lymphoblastic leukemia (ALL) following allogeneic hematopoietic stem cell transplantation, offering new hope in hematology.
Breakthrough Advances in Natural Killer (NK) Cells Over 50 Years
Over the past five decades, research on Natural Killer (NK) cells has revolutionized our understanding of innate immunity, offering promising new avenues for cancer and viral therapies.
Breakthrough in Pediatric Autoimmune Disease: CAR-T Cell Therapy Cures Lupus Patient
A pioneering study at Erlangen University Hospital successfully treated a 16-year-old girl with severe systemic lupus erythematosus (SLE) using CAR-T cell therapy. This marks the first use of this treatment for pediatric lupus, offering new hope for children with autoimmune diseases.
Enhancing the Effectiveness of PROTAC: A Groundbreaking Study
A recent study in Nature Communications reveals key insights into the intrinsic signaling pathways that modulate the effectiveness of targeted protein degradation using PROTACs. This discovery could pave the way for more effective treatments for cancer and other diseases.
Promoting Health and Recovery: Daily Care for Leukemia Patients
Ensuring a safe and comfortable treatment experience for leukemia patients involves meticulous daily care, including environmental sanitation, personal hygiene, nutrition, and appropriate exercise. This guide provides essential tips for effective daily care to support recovery.
Groundbreaking Results of CD7-Targeted CAR-T Therapy for T-ALL and T-LBL
A recent study highlights the promising results of CD7-targeted chimeric antigen receptor (CAR) T cell therapy in treating patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).
Coverage of the 2024 ASH Annual Meeting and Exposition
The 66th Annual Meeting of the American Society of Hematology (ASH) will be held from December 7-10, 2024, at the San Diego Convention Center, showcasing groundbreaking research and advancements in hematology.
New Hope in Cancer Treatment: TILs Therapy Emerges as the Next Frontier
Despite the ongoing challenges in industrialization and commercialization, CAR-T therapy's limitations are being addressed by a promising new approach: Tumor-Infiltrating Lymphocyte (TIL) therapy. This breakthrough heralds a new era in the fight against solid tumors.
Are Cellular Therapies the Future of Autoimmune Disease?
A revolutionary treatment for cancers may also be able to treat and reset the immune system to provide long-term remission or possibly even cure certain autoimmune diseases.
